Odyssey Therapeutics, Inc. 8-K

What Happened
Odyssey Therapeutics, Inc. announced its financial results for the three months ended March 31, 2026 in a press release dated June 17, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8-K filed June 17, 2026. The 8-K states the information is being furnished (not “filed”) under the Exchange Act.

Key Details

• Announcement date: June 17, 2026.
• Period covered: three months ended March 31, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K signed by Jason Haas, Chief Financial Officer, on June 17, 2026.
• The 8-K expressly notes the furnished information is not subject to Section 18 liability and is not incorporated by reference elsewhere unless expressly stated.

Why It Matters
This filing signals Odyssey has released its latest quarterly results (earnings/revenue and other financial metrics) to investors; the detailed figures and commentary will be in the furnished press release. Because the 8-K is furnished rather than filed, the company limits certain legal liabilities for the disclosed information. Investors should read the Exhibit 99.1 press release for the specific revenue, expenses, cash position, and management commentary to assess near‑term performance and outlook.